Renninger Robert 4

What Happened
Robert Renninger, Chief Financial Officer of LeonaBio, was granted a derivative award on April 9, 2026: an option to acquire 300,000 shares of LeonaBio at an exercise price of $0.00. No cash was paid at grant (reported acquisition value $0). This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-09; Form 4 filed: 2026-04-13 (timely).
• Transaction type: Grant/Award (derivative option) for 300,000 shares at $0.00 per share.
• Shares owned after transaction: Not reported in the filing.
• Footnote: The option vests monthly over 48 months on each monthly anniversary of the grant date, subject to continued service under the Issuer's 2026 Equity Incentive Plan.
• No indication of immediate sale or cashless exercise; award appears to be a long-term incentive.

Context
This is a routine equity-compensation grant to an executive and should be viewed as part of pay and retention incentives rather than an independent market purchase signal. Because it is a derivative award with multi-year vesting, it aligns the CFO’s potential equity stake with long-term performance and continued service.